Predicting Cognitive Resilience Against Sleep Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01651429|
Recruitment Status : Completed
First Posted : July 27, 2012
Last Update Posted : June 16, 2014
|Condition or disease||Intervention/treatment||Phase|
|Sleep Deprivation||Behavioral: Sleep deprivation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multimodal Neuroimaging to Predict Cognitive Resilience Against Sleep Loss|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||June 2014|
Experimental: Sleep deprivation
Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
Behavioral: Sleep deprivation
Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
- Differences in the medial prefrontal cortex (MPFC) as measured by fMRI, DTI, and MRS [ Time Frame: Session 2 of study (1 week after enrollment) ]It is hypothesized that, relative to vulnerable individuals, those who are highly resistant to the adverse effects of sleep loss on cognition will show: 1) increased gray matter volume in the MPFC, 2) greater white matter integrity as indicated by the Diffusion Tensor Imaging measure of fractional anisotropy (FA) values in the MPFC, 3) greater functional activation in MPFC during cognitively demanding tasks, 4) greater functional connectivity between MPFC and alerting regions of the midbrain and thalamus; and 5) different ratios of GABA and glutamate within the MPFC.
- Psychomotor Vigilance Task (PVT) [ Time Frame: At sleep deprivation session (2 weeks after enrollment) ]The PVT will be administered 17 throughout the overnight sleep deprivation session. PVT performance measures participants' alertness and objective resilience to sleep deprivation. PVT performance will be used as a measure to retrospectively assign participants into sleep loss-resistant and sleep loss-vulnerable groups.
- Karolinska Sleepiness Scale (KSS) [ Time Frame: At sleep deprivation session (2 weeks after enrollment) ]The KSS will be administered 17 throughout the overnight sleep deprivation session. The KSS provides a measure of subjective sleepiness.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01651429
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Principal Investigator:||William D Killgore, PhD||Mclean Hospital|